We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $41.51 in the latest trading session, marking a -0.06% move from the prior day. The stock lagged the S&P 500's daily gain of 0.57%. At the same time, the Dow added 0.23%, and the tech-heavy Nasdaq gained 0.99%.
Prior to today's trading, shares of the drugmaker had gained 3.93% over the past month. This has lagged the Medical sector's gain of 4.65% and outpaced the S&P 500's gain of 3.01% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be October 30, 2018. The company is expected to report EPS of $0.75, up 11.94% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.51 billion, up 2.63% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.99 per share and revenue of $54.25 billion. These results would represent year-over-year changes of +12.83% and +3.23%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.05% higher within the past month. PFE is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 13.88 right now. For comparison, its industry has an average Forward P/E of 16.15, which means PFE is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 2.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 117, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE - Free Report) closed at $41.51 in the latest trading session, marking a -0.06% move from the prior day. The stock lagged the S&P 500's daily gain of 0.57%. At the same time, the Dow added 0.23%, and the tech-heavy Nasdaq gained 0.99%.
Prior to today's trading, shares of the drugmaker had gained 3.93% over the past month. This has lagged the Medical sector's gain of 4.65% and outpaced the S&P 500's gain of 3.01% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be October 30, 2018. The company is expected to report EPS of $0.75, up 11.94% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.51 billion, up 2.63% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.99 per share and revenue of $54.25 billion. These results would represent year-over-year changes of +12.83% and +3.23%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.05% higher within the past month. PFE is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 13.88 right now. For comparison, its industry has an average Forward P/E of 16.15, which means PFE is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 2.01. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 117, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.